A review of multiple sclerosis with asian perspective

Medical Journal of Malaysia

Volumn 63, Issue 5, 2008, Pages 356-361

  Chong, H T ^a,b   Tan, Chong Tin ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Asian; Multiple sclerosis; Neuromyelitis optica

Indexed keywords

ALEMTUZUMAB; AMANTADINE; AZATHIOPRINE; BACLOFEN; BETA INTERFERON; BETA1A INTERFERON; BISACODYL; CALCIUM CHANNEL BLOCKING AGENT; CINNARIZINE; CLADRIBINE; DACLIZUMAB; DANTROLENE; DESMOPRESSIN; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MEMANTINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OXYBUTYNIN; PREDNISOLONE; PROCHLORPERAZINE; PROSTAGLANDIN E1; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TIZANIDINE; UNINDEXED DRUG;

ASIA; BLADDER SPASM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DIETARY FIBER; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPHAGIA; ETHNIC DIFFERENCE; FATIGUE; GASTROTOMY; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; LOW DRUG DOSE; MULTIPLE SCLEROSIS; MUTATIONAL ANALYSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; NOCTURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATHOPHYSIOLOGY; PELVIC FLOOR MUSCLE TRAINING; PHYSICAL DISABILITY; PHYSIOTHERAPY; PLASMAPHERESIS; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPASTICITY; VERTIGO;

HUMANS; MALAYSIA; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 60849084581     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Kurtzke JF and Wallin MT. Epidemiology. In Burks JS and Johnson KP (ed) Multiple Sclerosis: Diagnosis, Medical Management and Rehabilitation. Demos, New York. 2000.
2. Chong HT, Li PCK, Ong B et al. Severe spinal cord involvement is a universal feature of Asians with multiple sclerosis: A joint Asian Study. Neurol J Southeast Asia 2002; 7: 35-40.
3. Román GC, Castellanos-Mateus P. Multiple Sclerosis in Feigin VL and Bennett DA. (ed) Handbook of Clinical Neuroepidemiology. Nova Science Publisher, New York, 2007.
4. Cheng Q, Miao L, Zhang J et al A population-based survey of multiple sclerosis in Shanghai, China. Neurology 2007; 68: 1495-500.
5. Kira J. Epidemiology of multiple sclerosis in Japanese: with special reference to opticospinal multiple sclerosis. Rinsho Shinkeigaku - Clinical Neurology 2006; 46(11): 859-62.
6. Tan CT. Multiple sclerosis in Malaysia. Arch Neurol 1988; 45: 624-27.
7. Tan CT. Multiple sclerosis in Malaysia. Neurol J Southeast Asia 1997; 2: 1-5.
8. Peltonen, L. Old suspects found guilty - The first genome profile of multiple sclerosis. N Eng J Med, 2007; 357 (9): 927-29.
9. The International Multiple Sclerosis Genetic Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Eng J Med, 2007; 357(9): 851-62.
10. Kurtzke JF and Hyllested K. Multiple sclerosis in the Faroe Island: Clinical and epidemiological features. Ann Neurol, 1979; 5 (1): 6-21.
11. Monger KL, Levin LI, Hollis BW et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-38.
12. Munger KL, Zhang SM, O'Reilly S et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62: 60-65.
13. Brück, W. Clinical implications of neuropathological findings in multiple sclerosis. J Neurol 2005; 252 (Suppl 3): III 10 - III 14.
14. Trapp, BD, Peterson J, Ransohoff RM et al. Axonal transaction in the lesions of multiple sclerosis. N Eng J Med, 1998; 338: 278-85.
15. Kornek B and Lassmann H. Neuropathology of multiple sclerosis - new concepts. Brain Research Bulletin 2003; 61: 321-26.
16. Lisak RP. Neurodegeneration in multiple sclerosis. Neurology 2007; 68 (Suppl 3): S5-S12.
17. Barnett MH and Prineas JW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-68.
18. Matute C. and Pérez-Cerdá F. Multiple sclerosis: Novel perspective on newly forming lesions. Trends in Neurosciences 2005; 28(4): 173-75.
19. Paty DW. Initial Symptoms. In Multiple Sclerosis: Diagnosis, Medical Management and Rehabilitation by Burks JS and Johnson KP. Demos, New York, 2000.
20. Tan CT. Paroxysmal tonic seizures in demyelinating disease. Singapore Med J, 1986; 27(3): 256-8.
21. Ho JSF and Tan CT. Visual function among multiple sclerosis patients in Malaysia. Neurol J Southeast Asia 2000; 5: 35-40.
22. Bitsch A and Brück W. Differentiation of multiple sclerosis subtypes. CNS Drug 2002; 16(6): 405-18.
23. Polman CH, Reingold SC, Eden G et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald's Criteria". Ann Neurol 2005; 58: 840-46.
24. Chong HT, N Ramli, KR Lee et al. Magnetic resonance imaging of Asians with multiple sclerosis was similar to that of the West. Neurol Asia 2004; 9: 47-53.
25. Chong HT, N Ramli, KR Lee et al. Low sensitivity of McDonald MRI criteria in the diagnosis of multiple sclerosis among Asians. Neurol Asia 2006; 11: 129-33.
26. Chong HT, Li PCK, Singhal BJ, Kira J, Saida T, Kim BJ, Lee KH, Ong BKC, Tsai CP, Prayoonwiwat N and Tan CT. Proposed modifications to McDonald diagnostic criteria for Asians with multiple sclerosis. Neurol Asia 2006; 11: 87-90.
27. Cree BAC, Goodin DS and Hauser SL. Neuromyelitis optica. Seminar in Neurology 2002; 22(2): 105-22.
28. de Seze J. Neuromyelitis optica. Arch Neurol 2003; 60: 1336-38.
29. O'Riordan JL, Gallagher HL, Thompson AJ, Howard KS, Kingsley DP, Thompson EJ, McDonald WI, Miller DH Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60(4): 382-7.
30. Fazekas F, Offenbacher H, Schmidt R et al. MRI of neuromyelitis optica: evidence for a distinct entity. J Neurol Neurosurg Psychiatry 1994; 57(9): 1140-2.
31. Filippi M, Rocca MA, Moiola L, Martinelli V, Ghezzi A, Capra R, Salvi F, Comi G. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 1999; 53(8): 1705-10.
32. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-112.
33. Weinshenker BG, Wingerchuk DM, Nakashima I et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurology 2006; 5: 110-111.
34. Ikuda F, Koga M, Takeda S et al. "Comparison of MS pathology between 70 American and 75 Japanese autopsy cases" in Kuroiwa Y and Kurland LT (ed) Multiple Sclerosis East and West: Proceedings of the Asian Multiple Sclerosis Workshop and Satellite Symposium, Multiple Sclerosis, 12th World Congress of Neurology. Karger, Basel 1981.
35. Chong HT, Kermode A and Tan CT. The role of anti-aquaporin-4 antibody in Asian patients with multiple sclerosis: Confusions and controversies. Neurology Asia 2007; 12: 135-39.
36. Murray TJ. Diagnosis and treatment of multiple sclerosis (Clinical Review). BMJ 2006; 332: 525-7.
37. Lehmann HC, Hartung H-P, Hetzel GR, Stüve O and Kieseier BC. Plasma exchange in neuroimmunological disorders. Arch Neurol 2006; 63: 930-35.
38. Calabresi PA. Considerations in the treatment of relapsing remitting multiple sclerosis. Neurology 2002; 58(Suppl 4): S10-S22.
39. Tourbah A and Lyon-Caen O. Interferons in multiple sclerosis: Ten years' experience. Biochimie 2007; 89: 899-902.
40. Pozzilli C, Prosperini L, Sbardella E and Paolillo A. Inteferon after 10 years in patients with multiple sclerosis. Neurol Sci 2006; 27: S369-72.
41. Durelli L, Verdun E, Barbero P et al. Every other day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60.
42. Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78.
43. Comi G. Future therapies in multiple sclerosis: Early treatment. Neurol Sci 2006; 27: S8-S12.
44. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Eng J Med, 2000; 343: 898-904.
45. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
46. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-49.
47. Rudick RA, Stuart WH, Calabresi PA et al for the SENTINEL investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Eng J Med, 2006; 354: 911-23.
48. Miller DH, Khan OA, Sheremata WA et al for the International Natalizumab Multiple Sclerosis Trial Group. N Eng J Med, 2003; 348: 15-23.
49. Kappos L, Bates D, Hartung H-P et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurology 2007; 6: 431-41.
50. Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2005; online publication: DOI 10.1007/ s00415-005-0934-5.
51. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE and Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785-89.
52. Rizvi SA and Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 2004; 63 (Suppl 6): S47-S54.
53. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Eng J Med, 2006; 335: 1124-40.
54. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G and Filippi M. Secondary progressive multiple sclerosis: Current knowledge and future challenges (review). Lancet Neurology 2006; 5: 343-54.
55. Karussis D, Grigoriadis S, Polyzoidou E, Grigoriadis N, Slavin S and Abramsky O. Neurprotection in multiple sclerosis. Clinical Neurology and Neurosurgery 2006; 180: 250-54.
56. Thompson AJ. Symptomatic management and rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71 (Suppl II): ii22-ii27.
57. Vukusic S and Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Current Opinion in Neurology 2007; 20: 269-74.
58. Confavreux C, Vukusic S, Moreau T and Adeleine P. Relapses and progression of disability in multiple sclerosis. N Eng J Med, 2000; 343: 1430-8.
59. Tan CT. Prognosis of patients who present with an episode of myelopathy of unknown origin in Malaysia: a retrospective study of 52 patients. Aust NZ J Med 1989; 19: 297-302.
60. Chong HT, Li PCK, Ong B et al. Long term outcome of multiple sclerosis in Asia. Neurol Asia 2006; 11: 49-53.